Acadia might be the natural buyer but I don't believe for one second that they are the only ones that know what this is worth. I am certain other pharmas are acutely aware of the potential of this neuroscience and recent phase 3 trial success. Will they sit on their hands and wait for the FDA approval stage and possibly miss the opportunity or jump now with an offer whilst completing DD? I tend to agree with the camp that believe an offer may be closer than we think. Either way just happy for Rett community and fellow SH's the trials have been completed successfully.
NEU Price at posting:
$3.20 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)